Merck (MRK) is licensing the experimental skin-patch vaccination developed by Australia's Vaxxas to further fund research, including human tests, Vaxxas says. The Nanopatch system could protect against disease with only a small percentage of antigens required in needle-based vaccination, and might be cheaply manufactured and even mailed out in case of a flu pandemic.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Feb 24, 2015)
at MarketWatch.com (Feb 23, 2015)
at CNBC.com (Feb 4, 2015)
at MarketWatch.com (Feb 2, 2015)
at Nasdaq.com (Jan 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs